New IBD Drug's Real-World impact under the microscope
NCT ID NCT07102368
Summary
This study follows 400 people with Crohn's disease or ulcerative colitis who are starting treatment with guselkumab in real-world medical settings. The main goal is to see how well the drug controls symptoms like abdominal pain, diarrhea, and rectal bleeding, and to measure its impact on daily life, fatigue, and work productivity. Researchers will track how long patients stay on the treatment and monitor for any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Praxis Fur Gastroenteroligie
RECRUITINGBerlin, 10825, Germany
Conditions
Explore the condition pages connected to this study.